1170 No MED-6 22 0

Enzymatic Therapy @

January 11, 2003

Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration Attention: Robert Moore 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	<u>STATEMENTS</u>
Enzymatic Therapy, Inc.	Acidophilus Pearls™	Proprietary Problotic Blend Lactobacillus acidophilus and Bifdobacterium longum	The patented seamless pearl capsule of Acidophilus Pearls™ assures that virtually all the bacteria remain uninjured and healthy to colonize in the intestine.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By:

Robert Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/11/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Sincerely,

Michael P. Devereux Chief Financial Officer Acidophilus Pearls with patented True Delivery Technology 24e

975 0162 LET /1392

x3181

January 9, 2003

Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration Attention: Robert Moore 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

3.8 1 9 E The

	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Acidophilus Pearls™	Proprietary Probiotic Blend Lactobacillus acidophilus and Bifdobacterium longum	Lactobacillus acidophilus and Bifidobacterium longum also help support the better utilization and bioavailability of nutrients, including vitamins, minerals, proteins, fats, and carbohydrates.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By

Robert Doster Title: Senior Vice President of Scientific Affairs

Date: 1/9/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Sincerely, wenn

Michael P. Devereux Chief Financial Officer Acidophilus Pearls with patented True Delivery Technology 22e

January 10, 2003

Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration Attention: Robert Moore 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Acidophilus Pearls™	Proprietary Probiotic Blend Lactobacillus acidophilus and Bifdobacterium longum	Probiotics have been shown to help retain healthy levels of C. albicans that are already within normal limits.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By:

' Robert Doster Title: Senior Vice President of Scientific Affairs

Date: 1/10/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely, . Jevenn

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Michael P. Devereux Chief Financial Officer

January 8, 2003

Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration Attention: Robert Moore 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Acidophilus Pearls™	Proprietary Probiotic Blend Lactobacillus acidophilus and Bifdobacterium longum	Oral ingestion of probiotics produces a stabilizing effect on the gut flora.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By:

Robert Doster Title: Senior Vice President of Scientific Affairs

1/8/03 Date:

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely,

Michael P. Devereux Chief Financial Officer

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Acidophilus Pearls with patented True Delivery Technology 21e

January 7, 2003

Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration Attention: Robert Moore 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

	PRODUCT NAME		STATEMENTS
Enzymatic Therapy, Inc.	Acidophilus Pearls™	Proprietary Probiotic Blend Lactobacillus acidophilus and Bifdobacterium longum	In an open, randomized, controlled trial, Lactobacillus acidophilus and Bifidobacterium bifidum were supportive of colon health in older adults.* In addition, B cell (important antibody producing immune cells) levels increased as compared with the untreated group.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By:

Title: Senior Vice President of Scientific Affairs

Date: 1/7/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely,

Michael P. Devereux Chief Financial Officer

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Acidophilus Pearls with patented True Delivery Technology 20c

January 6, 2003

Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration Attention: Robert Moore 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

с. С. / .

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Acidophilus Pearls™	Proprietary Probiotic Blend Lactobacillus acidophilus and Bifdobacterium longum	Lactobacillus acidophilus and Bifidobacterium longum have been shown to possess immunoprotective/immunomodulatory properties.* These benefits include modulation of: cytokine and various interleukin production, autoimmunity, natural killer cell cytotoxicity, lymphocyte proliferation, and antibody production.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By:

Robert Doster

Title: Senior Vice President of Scientific Affairs

11103 Date:

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Sincerely, [even

Michael P. Devereux Chief Financial Officer Acidophilus Pearls with patented True Delivery Technology 19e

January 5, 2003

Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration Attention: Robert Moore 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

<u>COMPANY</u>	PRODUCT NAME	DIETARY INGREDIENTS	<u>STATEMENTS</u>
Enzymatic Therapy, Inc.	Acidophilus Pearls™	Proprietary Probiotic Blend Lactobacillus acidophilus and Bifdobacterium longum	In a randomized, controlled clinical trial, Bifidobacterium longum was shown to support the breakdown of lactose and reduce the symptoms of lactose intolerance (flatulence) in people with lactose intolerance.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By:

Robert Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/5/03

0.0

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Sincerely, . Jevenn

Michael P. Devereux Chief Financial Officer Acidophilus Pearls with patented True Delivery Technology 18e

January 4, 2003

Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration Attention: Robert Moore 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Acidophilus Pearls™	Proprietary Probiotic Blend Lactobacillus acidophilus and Bifdobacterium longum	Probiotics do not permanently colonize in the body. Therefore, they need to be ingested regularly for their health-promoting effects to persist.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

Bv:

Robert Doster Title: Senior Vice President of Scientific Affairs

Date: 1/4/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely,

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Michael P. Devereux Chief Financial Officer

Acidophilus Pearls with patented True Delivery Technology 17e

January 3, 2003

Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration Attention: Robert Moore 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

<u>COMPANY</u>	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Acidophilus Pearls™	Proprietary Probiotic Blend Lactobacillus acidophilus and Bifdobacterium longum	Additionally, the patented True Delivery [™] Technology pearl capsule protects the bacteria from harsh stomach acid so they can be released live and intact in the intestines, where they need to arrive in live form to perform their beneficial function.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By:

Robert Doster Title: Senior Vice President of Scientific Affairs

Date: 1/3/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely,

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Chief Financial Officer

Acidophilus Pearls with patented True Delivery Technology 16e

January 2, 2003

Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration Attention: Robert Moore 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Acidophilus Pearls™	Proprietary Probiotic Blend Lactobacillus acidophilus and Bifdobacterium longum	It provides a combination of two different active, live cultures to support the overall health of the intestinal tract.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By:

Robert Doster Title: Senior Vice President of Scientific Affairs

1/2/03 Date:

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com Sincerely, Michael P. Jevenn

Michael P. Devereux Chief Financial Officer

Acidophilus Pearls with patented True Delivery Technology 15e

January 1, 2003

.

Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration Attention: Robert Moore 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Acidophilus Pearls™	Proprietary Probiotic Blend Lactobacillus acidophilus and Bifdobacterium longum	Acidophilus Pearls™ is a probiotic dietary supplement designed to help support digestion and a healthy intestinal system.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

Bv:

Robert Doster Title: Senior Vice President of Scientific Affairs

1/103 Date:

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Sincerely,

Michael P. Devereux Chief Financial Officer

Acidophilus Pearls with patented True Delivery Technology 14e